Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
631
archived clinical trials in
Vaccines

MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated:  12/31/1969
UF Health Pediatrics - Gerold L. Schiebler CMS Center
2453
mi
from 98109
Gainesville, FL
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated: 12/31/1969
UF Health Pediatrics - Gerold L. Schiebler CMS Center
2453
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated:  12/31/1969
UF Health Pediatrics - Tower Square
2451
mi
from 98109
Gainesville, FL
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated: 12/31/1969
UF Health Pediatrics - Tower Square
2451
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated:  12/31/1969
UF Family Medicine - Eastside
2453
mi
from 98109
Gainesville, FL
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated: 12/31/1969
UF Family Medicine - Eastside
2453
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2072
mi
from 98109
Birmingham, AL
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
981
mi
from 98109
Anaheim, CA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
981
mi
from 98109
Anaheim, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
974
mi
from 98109
Paramount, CA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
974
mi
from 98109
Paramount, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
626
mi
from 98109
Sacramento, CA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
626
mi
from 98109
Sacramento, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
710
mi
from 98109
San Jose, CA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
710
mi
from 98109
San Jose, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
397
mi
from 98109
Nampa, ID
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
397
mi
from 98109
Nampa, ID
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1420
mi
from 98109
Newton, KA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1420
mi
from 98109
Newton, KA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1453
mi
from 98109
Topeka, KA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1453
mi
from 98109
Topeka, KA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2024
mi
from 98109
Cleveland, OH
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2075
mi
from 98109
Erie, PA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2075
mi
from 98109
Erie, PA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2346
mi
from 98109
Cheraw, SC
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2346
mi
from 98109
Cheraw, SC
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
683
mi
from 98109
Layton, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
683
mi
from 98109
Layton, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
706
mi
from 98109
Murray, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
706
mi
from 98109
Murray, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
731
mi
from 98109
Orem, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
731
mi
from 98109
Orem, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
736
mi
from 98109
Provo, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
736
mi
from 98109
Provo, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
678
mi
from 98109
Syracuse, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
678
mi
from 98109
Syracuse, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1542
mi
from 98109
Marshfield, WI
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1542
mi
from 98109
Marshfield, WI
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2415
mi
from 98109
North Charleston, SC
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2415
mi
from 98109
North Charleston, SC
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1506
mi
from 98109
Kansas City, MO
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1506
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
3424
mi
from 98109
San Jose,
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
3424
mi
from 98109
San Jose,
Click here to add this to my saved trials
Phase 1 Safety Study of Two Experimental HIV Vaccines
VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Phase 1 Safety Study of Two Experimental HIV Vaccines
VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
CU Center for Midwifery
1026
mi
from 98109
Aurora, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
CU Center for Midwifery
1026
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
CU Maternal and Fetal Medicine Clinic
1027
mi
from 98109
Aurora, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
CU Maternal and Fetal Medicine Clinic
1027
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
University Nurse Midwives
1026
mi
from 98109
Aurora, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
University Nurse Midwives
1026
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Boulder Women's Care
998
mi
from 98109
Boulder, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Boulder Women's Care
998
mi
from 98109
Boulder, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
St. Joe's Midwives
1021
mi
from 98109
Denver, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
St. Joe's Midwives
1021
mi
from 98109
Denver, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Partners in Women's Health at Rose
1023
mi
from 98109
Denver, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Partners in Women's Health at Rose
1023
mi
from 98109
Denver, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Colorado Mountain Medical
958
mi
from 98109
Edwards, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Colorado Mountain Medical
958
mi
from 98109
Edwards, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Bella Natural Women's Care
1024
mi
from 98109
Englewood, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Bella Natural Women's Care
1024
mi
from 98109
Englewood, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Associates in Women's Health
1013
mi
from 98109
Golden, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Associates in Women's Health
1013
mi
from 98109
Golden, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Women's Health Group Thornton
1015
mi
from 98109
Thornton, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Women's Health Group Thornton
1015
mi
from 98109
Thornton, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Atlanta Women's Specialists
2171
mi
from 98109
Alpharetta, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Atlanta Women's Specialists
2171
mi
from 98109
Alpharetta, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Roswell Ob/Gyn
2171
mi
from 98109
Alpharetta, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Roswell Ob/Gyn
2171
mi
from 98109
Alpharetta, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Athens Midwifery
2215
mi
from 98109
Athens, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Athens Midwifery
2215
mi
from 98109
Athens, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Athens Ob-Gyn
2215
mi
from 98109
Athens, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Athens Ob-Gyn
2215
mi
from 98109
Athens, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Women's Healthcare Associates of Athens
2214
mi
from 98109
Athens, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Women's Healthcare Associates of Athens
2214
mi
from 98109
Athens, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Riverbend OB/GYN and Counseling
2173
mi
from 98109
Atlanta, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Riverbend OB/GYN and Counseling
2173
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Peachtree Women's Clinic
2172
mi
from 98109
Cumming, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Peachtree Women's Clinic
2172
mi
from 98109
Cumming, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Comprehensive Women's OB/GYN
2178
mi
from 98109
Duluth, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Comprehensive Women's OB/GYN
2178
mi
from 98109
Duluth, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Dunwoody Ob-Gyn
2174
mi
from 98109
Dunwoody, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Dunwoody Ob-Gyn
2174
mi
from 98109
Dunwoody, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Atlanta Gynecology & Obstetrics
2184
mi
from 98109
Lilburn, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Atlanta Gynecology & Obstetrics
2184
mi
from 98109
Lilburn, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Women's Medical Center
2181
mi
from 98109
Tyrone, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Women's Medical Center
2181
mi
from 98109
Tyrone, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
The Emory Clinic
2180
mi
from 98109
Atlanta, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
The Emory Clinic
2180
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain OBGYN
mi
from 98109
Denver, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain OBGYN
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated:  12/31/1969
Duke University
2341
mi
from 98109
Durham, NC
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated: 12/31/1969
Duke University
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Accel Research Sites
2526
mi
from 98109
Birmingham, AL
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Accel Research Sites
2526
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials